Search Results - "PU, Xingxiang"

Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance by Pu, Xingxiang, Wu, Lin, Su, Dan, Mao, Weimin, Fang, Bingliang

“…Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the treatment of lung cancer, the leading cause of cancer-related deaths in the…”
Get full text

Clinical and genomic features of Chinese lung cancer patients with germline mutations by Peng, Wenying, Li, Bin, Li, Jin, Chang, Lianpeng, Bai, Jing, Yi, Yuting, Chen, Rongrong, Zhang, Yanyan, Chen, Chen, Pu, Xingxiang, Jiang, Meilin, Li, Jia, Zhong, Rui, Xu, Fang, Chen, Bolin, Xu, Li, Wang, Ning, Huan, Jiaojiao, Dai, Pingping, Guan, Yanfang, Yang, Ling, Xia, Xuefeng, Yi, Xin, Wang, Jiayin, Yu, Fenglei, Wu, Lin

“…The germline mutation landscape in Chinese lung cancer patients has not been well defined. In this study, sequencing data of 1,021 cancer genes of 1,794…”
Get full text

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study by Pu, Xingxiang, Zhou, Yu, Kong, Yi, Chen, Bolin, Yang, Aifang, Li, Jia, Li, Kang, Xu, Yan, Wu, Lin

“…Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations are harbored as uncommon mutations…”
Get full text

A real‐world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non‐small cell lung cancer by Zhang, Baihua, Xiao, Haifan, Pu, Xingxiang, Zhou, Chunhua, Yang, Desong, Li, Xu, Wang, Wenxiang, Xiao, Qin

“…Background The impact of neoadjuvant chemoimmunotherapy on pulmonary resection and related outcomes had been poorly reported in previous studies. The present…”
Get full text

ADAMTS4 exacerbates lung cancer progression via regulating c-Myc protein stability and activating MAPK signaling pathway by Zhai, Wei, Yang, Wensheng, Ge, Jing, Xiao, Xuelian, Wu, Kang, She, Kelin, Zhou, Yu, Kong, Yi, Wu, Lin, Luo, Shiya, Pu, Xingxiang

“…Lung cancer is one of the most frequent cancers and the leading cause of cancer-related deaths worldwide with poor prognosis. A disintegrin and…”
Get full text

Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy by Jiang, Meilin, Peng, Wenying, Pu, Xingxiang, Chen, Bolin, Li, Jia, Xu, Fang, Liu, Liyu, Xu, Li, Xu, Yan, Cao, Jun, Wang, Qianzhi, Li, Kang, Wang, Jingyi, Wu, Lin

“…Background: Selecting patients who potentially benefit from immune checkpoint inhibitors (ICIs) is critical. Programmed death ligand-1 (PD-L1) protein…”
Get full text

Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma by Jiang, Meilin, Yang, Pei, Li, Jing, Peng, Wenying, Pu, Xingxiang, Chen, Bolin, Li, Jia, Wang, Jingyi, Wu, Lin

“…BackgroundBiomarkers that predict the efficacy of first-line tyrosine kinase inhibitors (TKIs) are pivotal in epidermal growth factor receptor (EGFR) mutant…”
Get full text

Case Report: Tissue Origin Identification for Cancer of Unknown Primary: Gene Expression Profiling Approach by Pu, Xingxiang, Yang, Sa, Xu, Yan, Chen, Bolin, Wang, Qianzhi, Gong, Qian, Wu, Lin

“…The treatment of cancer of unknown primary (CUP) is a huge challenge for clinicians. Gene expression profiling can help identify the tissue origin of tumors by…”
Get full text

Rh‐endostatin plus camrelizumab and chemotherapy in first‐line treatment of advanced non‐small cell lung cancer: A multicenter retrospective study by Pu, Xingxiang, Wang, QianZhi, Liu, Liyu, Chen, Bolin, Li, Kang, Zhou, Yu, Sheng, Zengmei, Liu, Ping, Tang, Yucheng, Xu, Li, Li, Jia, Kong, Yi, Xu, Fang, Xu, Yan, Wu, Lin

“…Background Clinical evidence of immune checkpoint inhibitors combined with antiangiogenic drugs in patients with advanced non‐small cell lung cancer (NSCLC)…”
Get full text

Prevalence and clinical significance of pathogenic germline BRCA1 / 2 mutations in Chinese non-small cell lung cancer patients by Hu, Xingsheng, Yang, Dongyong, Li, Yalun, Li, Li, Wang, Yan, Chen, Peng, Xu, Song, Pu, Xingxiang, Zhu, Wei, Deng, Pengbo, Ye, Junyi, Zhang, Hanhan, Lizaso, Analyn, Liu, Hao, Mao, Xinru, Huang, Hai, Chu, Qian, Hu, Chengping

“…Germline alterations in the breast cancer susceptibility genes type 1 and 2, and , predispose individuals to hereditary cancers, including breast, ovarian,…”
Get full text

Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study by Chen, Meiting, Chen, Yungchang, Fang, Xiaojie, Wang, Zhao, Pu, Xingxiang, Liang, Chaoyong, Guo, Hongqiang, Li, Qian, Pan, Fei, Hong, Huangming, Huang, He, Li, Jiman, Lin, Tongyu

“…Background Lymphoepithelioma-like carcinoma (LELC) is a rare and unique subtype of cancer that histologically resembles undifferentiated nasopharyngeal…”
Get full text

Perivascular epithelioid cell tumor of the lung: A case report and literature review by Yu, Shaofu, Zhai, Shasha, Gong, Qian, Hu, Xiaoping, Yang, Wenjuan, Liu, Liyu, Kong, Yi, Wu, Lin, Pu, Xingxiang

“…The perivascular epithelioid cell tumor (PEComa) is a rare tumor of interstitial origin characterized by several immunological and muscle cell markers. The…”
Get full text

Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer by Pu, Xingxiang, Zhang, Ran, Wang, Li, Chen, Yungchang, Xu, Yi, Pataer, Apar, Meraz, Ismail M, Zhang, Xiaoshan, Wu, Shuhong, Wu, Lin, Su, Dan, Mao, Weimin, Heymach, John V, Roth, Jack A, Swisher, Stephen G, Fang, Bingliang

“…Because patient-derived xenografts (PDXs) are grown in immunodeficient mouse strains, PDXs are regarded as lacking an immune microenvironment. However, whether…”
Get full text

The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses by Chen, Yungchang, Sun, Hao, Deng, Yanhong, Ma, Yutong, Huang, He, Liu, Yang, Zhang, Yaru, Zhang, Hongyu, Ye, Sheng, E, Mingyan, Guo, Hongqiang, Wu, Mengmeng, Wu, Chunman, Pu, Xingxiang, Chen, Xinggui, Liang, Chaoyong, Ou, Qiuxiang, Weng, Huawei, Wu, Xue, Shao, Yang, Gu, Anxin, Lin, Tongyu

“…BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common…”
Get full text

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor by Wang, Wenxian, Wang, Qian, Xu, Chunwei, Li, Ziming, Song, Zhengbo, Zhang, Yongchang, Cai, Xiuyu, Zhang, Shirong, Lian, Bin, Li, Wen, Liu, Anwen, Zhan, Ping, Liu, Hongbing, Lv, Tangfeng, Miao, Liyun, Min, Lingfeng, Chen, Yu, Yuan, Jingping, Wang, Feng, Jiang, Zhansheng, Lin, Gen, Pu, Xingxiang, Rao, Chuangzhou, Lv, Dongqing, Yu, Zongyang, Li, Xiaoyan, Tang, Chuanhao, Zhou, Chengzhi, Xie, Congying, Zhang, Junping, Guo, Hui, Chu, Qian, Meng, Rui, Wu, Jingxun, Zhang, Rui, Wang, Liping, Zhu, Youcai, Hu, Xiao, Xie, Yanru, Lin, Xinqing, Cai, Jing, Lan, Fen, Feng, Huijing, Wang, Lin, Yao, Wang, Shi, Xuefei, Huang, Jianhui, Chen, Huafei, Zhang, Yinbin, Sun, Pingli, Wan, Bing, Pang, Fei, Xu, Zanmei, Wang, Kai, Xia, Yuanli, Ye, Mingxiang, Wang, Dong, Wei, Qing, Feng, Shuitu, Zhou, Jianya, Zhang, Jiexia, Lv, Donglai, Gao, Wenbin, Kang, Jing, Yu, Genhua, Liang, Xianbin, Yu, Chengtao, Shi, Lin, Yang, Nong, Wu, Lin, Hong, Zhuan, Hong, Wei, Fang, Meiyu, Zhang, Yiping, Lu, Yuanzhi, Wang, Guansong, Ma, Shenglin, Si, Lu, Fang, Wenfeng, Song, Yong

“…Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With…”
Get full text

Potential Value of Neoadjuvant Immunochemotherapy in Patients with Driver Gene-positive Non-small Cell Lung Cancer by Zihan WEI, ZHOU, Yu, PU, Xingxiang, YAN, Xiang

“…背景与目的 我国非小细胞肺癌（non-small cell lung cancer, NSCLC）患者中携带驱动基因突变的比例很高，而这部分患者当前的新辅助治疗方案缺乏明显获益。本研究通过分析新辅助免疫联合化疗在驱动基因阳性NSCLC患者中的疗效及不良反应，探索其潜在应用价值。方法…”
Get full text

Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy by Yan, Xiang, Wang, Li, Zhang, Ran, Pu, Xingxiang, Wu, Shuhong, Yu, Lili, Meraz, Ismail M., Zhang, Xiaoshan, Wang, Jacqueline F., Gibbons, Don L., Mehran, Reza J., Swisher, Stephen G., Roth, Jack A., Fang, Bingliang

“…Anti-PD-1 and anti-PD-L1 immunotherapy has provided a new therapeutic opportunity for treatment of advanced-stage non-small cell lung cancer (NSCLC). However,…”
Get full text

Cyclin D1 G870A polymorphism and risk of nasopharyngeal carcinoma: a case-control study and meta-analysis by Liao, Dan, Wu, Yongfu, Pu, Xingxiang, Chen, Hua, Luo, Shengqun, Li, BinBin, Ding, Congcong, Huang, Guo-Liang, He, Zhiwei

“…Cyclin D1 (CCND1) plays a key role in cell cycle regulation. It is a well-established human oncogene which is frequently amplified or overexpressed in cancers…”
Get full text

Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial by Li, Xueying, Huang, He, Xu, Bing, Guo, Hongqiang, Lin, Yingcheng, Ye, Sheng, Yi, Jiqun, Li, Wenyu, Wu, Xiangyuan, Wang, Wei, Zhan, Hongyu, Xie, Derong, Peng, Jiewen, Cao, Yabing, Pu, Xingxiang, Guo, Chengcheng, Hong, Huangming, Wang, Zhao, Fang, Xiaojie, Zhou, Yong, Lin, Suxia, Liu, Qing, Lin, Tongyu

“…Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell…”
Get full text

High‐throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion by Song, Zhengbo, Xu, Chunwei, Pu, Xingxiang, Zhu, Youcai, Wang, Wenxian, Li, Xingliang, Gao, Yanqiu, Zhu, Wenliang, He, Yunwei, Wu, Lin, Mao, Li, Chen, Li, Chen, Ming

“…Abbreviations NGS next-generation sequencing SNV single nucleotide variation indel insertion-or-deletion PANO-Seq parallel amplification and numerically…”
Get full text